Scenarios that move IMVT
Immunovant, Inc. - Common Stock
Scenarios that move IMVT: 2 analyses, 0 positive, 2 negative.
- · argenx meets primary endpoint in Phase II celiac disease study — ▼ · impact -32 · confidence low · horizon immediate
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -22 · confidence low · horizon quarters